Role of almitrine bismesylate in managing refractory hypoxemia in COVID19 acute respiratory distress syndrome

摘要

In the ongoingCOVID19 pandemic dueto Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2),clinicians have been using several permutationsand combinations to dealwithCOVID19 Acute RespiratoryDistress Syndrome(ARDS). As thereis no evidence based anti-viral ora vaccineavailableat this moment, management is purely supportive based on existing evidence. Cliniciansall over the world have used non-invasive/invasive ventilationwith lung protectivestrategies using high FiO2 and positiveend expiratory pressure(PEEP),corticosteroids, inhaled nitric oxide(NO),extra-corporealmembrane oxygenation (ECMO),anticoagulants,antivirals, hydroxy-chloroquinesulphate, inflammatory inhibitors, serotherapywith variableresults.[1] Researchersarestillsearching and experimenting various pharmacologicalagents in variety of doses which could improveintrapulmonary shunting leading to refractory hypoxiainCOVID19 ARDS. Onesuch drug isalmitrine bismesylate.